EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A multi‐arm multi‐stage platform design that allows preplanned addition of arms while still controlling the family‐wise error

Peter Greenstreet iD, Thomas Jaki iD, Alun Bedding, Chris Harbron, Pavel Mozgunov iD

Statistics in Medicine · 2024

DOI: 10.1002/sim.10135 ↗

At a glance

Journal article in Statistics in Medicine, 2024. Written by Peter Greenstreet and 4 co-authors. Institution: Department of Mathematics and Statistics, Lancaster University, Lancaster, UK. Major MEDLINE topics: Research Design. Cited 5 times so far (Crossref); 46 references. The full text is freely available (open access, CC BY 4.0). Funded by: Medical Research Council, Engineering and Physical Sciences Research Council, National Institute for Health and Care Research.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

There is growing interest in platform trials that allow for adding of new treatment arms as the trial progresses as well as being able to stop treatments part way through the trial for either lack of benefit/futility or for superiority. In some situations, platform trials need to guarantee that error rates are controlled. This paper presents a multi‐stage design, that allows additional arms to be added in a platform trial in a preplanned fashion, while still controlling the family‐wise error rate, under the assumption of known number and timing of treatments to be added, and no time trends. A method is given to compute the sample size required to achieve a desired level of power and we show how the distribution of the sample size and the expected sample size can be found. We focus on power under the least favorable configuration which is the power of finding the treatment with a clinically relevant effect out of a set of treatments while the rest have an uninteresting treatment effect. A motivating trial is presented which focuses on two settings, with the first being a set number of stages per active treatment arm and the second being a set total number of stages, with treatments that are added later getting fewer stages. Compared to Bonferroni, the savings in the total maximum sample size are modest in a trial with three arms,

Subjects

MeSH terms (MEDLINE)

Research DesignHumansSample SizeComputer SimulationModels, StatisticalClinical Trials as TopicRandomized Controlled Trials as TopicAdaptive Clinical Trials as Topic

Author keywords

MAMSmulti‐armmulti‐stageplatform trialsstrong control of FWER

Authors and institutions

  • Department of Mathematics and Statistics, Lancaster University, Lancaster, UK.
  • Exeter Clinical Trials Unit, University of Exeter, Exeter, UK.
  • MRC Biostatistics Unit, University of Cambridge, Cambridge, UK.
  • University of Regensburg, Regensburg, Germany.
  • Roche Products Ltd, Welwyn Garden City, UK.

ORCID profiles: Peter Greenstreet, Thomas Jaki, Pavel Mozgunov

Funding

  • Medical Research Council
  • Engineering and Physical Sciences Research Council
  • National Institute for Health and Care Research

Cite

APA

Greenstreet, P., Jaki, T., Bedding, A., Harbron, C., & Mozgunov, P. (2024). A multi‐arm multi‐stage platform design that allows preplanned addition of arms while still controlling the family‐wise error. Statistics in Medicine. https://doi.org/10.1002/sim.10135

Vancouver

Greenstreet P, Jaki T, Bedding A, Harbron C, Mozgunov P. A multi‐arm multi‐stage platform design that allows preplanned addition of arms while still controlling the family‐wise error. Statistics in Medicine. 2024. doi:10.1002/sim.10135

BibTeX
@article{Greenstreet2024,
  author = {Greenstreet, Peter and Jaki, Thomas and Bedding, Alun and Harbron, Chris and Mozgunov, Pavel},
  title = {A multi‐arm multi‐stage platform design that allows preplanned addition of arms while still controlling the family‐wise error},
  journal = {Statistics in Medicine},
  year = {2024},
  doi = {10.1002/sim.10135}
}
Start for free →